联合检测血浆SFRP2、RNF180基因甲基化在胃癌临床诊断中的价值  

Value of Combined Detection of Plasma SFRP2,RNF180 Gene Methylation in Clinical Diagnosis of Gastric Cancer

作　　者：宋毓飞[1] 张谢[1] 孙蓓蕾[1] 张学松[1] 黄诗良[1] 黄志刚[1] 

机构地区：[1]宁波市医疗中心李惠利医院消化内科,315040

出　　处：《胃肠病学》2015年第1期19-23,共5页Chinese Journal of Gastroenterology

基　　金：宁波市自然基金项目(2012A610212);宁波市科技创新团队(2013B82010)资助

摘　　要：背景：胃癌是一种常见的恶性肿瘤,其发病率和死亡率均较高.启动子区异常甲基化导致基因沉默在肿瘤发生、发展中起重要作用.目的：探讨联合检测血浆SFRP2和RNF180基因启动子区甲基化在胃癌早期筛查和临床诊断中的应用价值.方法：收集2011年6月-2013年6月宁波市医疗中心李惠利医院67例胃癌患者和51名健康志愿者的血浆标本,采用甲基化特异性PCR（MSP）法检测血浆中SFRP2、RNF180甲基化水平,并分析其与临床病理特征的相关性.结果：胃癌患者血浆中SFRP2、RNF180基因启动子区甲基化发生率分别为67.2％和53.7％,明显高于健康志愿者的37.3％和23.5％,差异均有统计学意义（P＜0.01）.胃癌患者SFRP2甲基化率与所有临床病理特征均无关（P＞0.05）,RNF180甲基化率与肿瘤大小、临床分期、分化程度、淋巴结转移、远处转移相关（P＜0.01）.联合检测SFRP2、RNF180基因甲基化能提高胃癌临床诊断率,优于单一基因检测（OR =5.6,95％ CI：2.1 ～14.8,P＜0.01）.结论：联合检测胃癌血浆中SFRP2、RNF180基因启动子区甲基化水平可提高胃癌检出率,是一种简单、非侵入的方法,可用于胃癌患者的临床早期筛查和诊断.Gastric cancer （GC） is one of the common malignancies with high morbidity and mortality. Gene silencing induced by aberrant methylation of gene promoter region has been found to be crucial in tumorigenesis. Aims： To investigate the value of combined detection of plasma SFRP2, RNF180 gene promoter region methylation in screening and clinical diagnosis of early GC. Methods： Plasma samples from 67 patients with GC and 51 normal individuals from June 2011 to June 2013 in Ningbo Medical Treatment Center Lihuili Hospital were obtained. Methylation specific PCR （MSP） technique was used to detect methylation of plasma SFRP2, RNF180 gene promoter region, and their correlations with clinicopathological parameters in GC were analyzed. Results： Plasma SFRP2, RNF180 gene promoter region methylation rates were significantly higher than those in controls （67.2% vs. 37.3% , 53.7% vs. 23.5% , P 〈0. O1 ）. No association was found between methylation rate of plasma SFRP2 and all the clinicopathological parameters in GC patients （ P 〉 0.05 ）. However, RNF180 methylation rate was positively correlated with tumor size, TNM stage, differentiation, lymph node metastasis and distant metastasis （P 〈 0.01 ）. Combined detection of SFRP2 and RNF180 gene methylation could increase the clinical diagnosis rate of GC, and was superior to that of single gene methylation detection （ OR = 5.6, 95% CI： 2.1- 14.8, P 〈 O. O1 ）. Conclusions： Combined detection of plasma SFRP2 and RNF180 gene promoter region methylation can increase the diagnosis rate of GC, and can be used as a simple and non-invasive method for clinical screening and diagnosis of early GC.

关 键 词：胃肿瘤 SFRP2基因 RNF180基因 DNA甲基化 诊断 

分 类 号：R735.2[医药卫生—肿瘤]